Search SAMHSA Publications and Digital Products
Store Facets Summary
Main page content
Published: June 2022Tarjeta de bolsillo con imagen de 988 Línea de Prevención del Suicido y Crisis This 2-sided 3.5"x2" business-sized wallet card helps publicize the 988 Suicide & Crisis Lifeline. Esta tarjeta de bolsillo de 2 caras de 3,5 "x2" ayuda a publicitar el nuevo Línea de Prevención del Suicido y Crisis. This item comes in packs of 50.
Preliminary Findings from Drug-Related Emergency Department Visits, 2021: Results from the Drug Abuse Warning Network
Published: May 2022An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3) the identification of drugs new to DAWN’s Drug Reference Vocabulary.
Published: April 2022This document provides an overview of essential information necessary for understanding mental health and substance use disorder parity and how to implement and comply with federal parity laws. This guide applies to parity laws in employer-sponsored health plans and group and individual insurance.
Published: April 2022There are protections in federal law, collectively known as “parity,” which are designed to ensure that certain types of health plans cover mental and substance use disorders no less generously than they cover other health issues. This resource can guide you to helpful materials and places.
Published: November 2021This Advisory reviews the evidence on prescription stimulant misuse among youth and young adults. It establishes prescription stimulant misuse as a public health problem, identifies associated risk and protective factors, and provides programs and action steps for stakeholders to prevent misuse.
Published: October 2021This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
Published: August 2021The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.